Intranasal CBD Delivery for Brain Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering Cannabidiol (CBD) to treat brain-related conditions face challenges due to poor bioavailability, as CBD has limited ability to cross the blood-brain barrier when taken orally or through conventional nasal sprays.
Innovation Solution
Direct nose-to-brain delivery of CBD by administering it to the upper third of the nasal passage, which allows CBD to bypass systemic metabolism and directly transit the blood-brain barrier, thereby achieving higher bioavailability in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If CBD is administered orally or through conventional nasal sprays, then the drug can be delivered to the body, but the bioavailability in the brain is poor due to limited ability to cross the blood-brain barrier and systemic metabolism
Solution Approach 1:
The nasal cavity is segmented into different regions, and the invention specifically targets the upper third of the nasal passage for direct brain delivery, separating this function from conventional nasal spray delivery to the lower regions that lead to systemic circulation
Solution Approach 2:
The nasal mucosa in the upper third of the nasal passage serves as an intermediary pathway that allows CBD to directly access the brain through the olfactory nerve pathway, bypassing the blood-brain barrier limitations of oral administration
2Ease of operation
If CBD is administered orally, then the drug can be easily administered, but only 6-13% bioavailability is achieved due to poor absorption and first-pass metabolism
Solution Approach 1:
The nasal mucosa acts as an intermediary absorption surface that bypasses hepatic first-pass metabolism, allowing CBD to enter systemic circulation and reach the brain with significantly higher bioavailability while maintaining ease of administration
Solution Approach 2:
The invention transitions from oral (gastrointestinal) absorption to nasal (mucosal) absorption, utilizing a different anatomical dimension and physiological pathway to achieve superior bioavailability
3Ease of operation
If conventional nasal sprays are used to deliver CBD, then the drug can be administered nasally, but poor Cmax is achieved when compared to IV administration
Solution Approach 1:
The invention applies local quality by specifically targeting the upper third of the nasal passage with different properties (direct brain access) compared to the lower nasal regions (systemic circulation), optimizing the delivery location to achieve higher Cmax
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly enhances the bioavailability of CBD in the brain, allowing for more effective treatment of brain-related conditions such as Parkinson's disease, ADHD, depression, and other neurological disorders with potentially fewer side effects.
Implementation Method 1
Direct nose-to-brain delivery of CBD by administering it to the upper third of the nasal passage, which allows CBD to bypass systemic metabolism and directly transit the blood-brain barrier
Data Source
AI summary
Methods of treating central nervous system (CNS) conditions associated with oxidative stress are provided by delivering Cannabidiol (CBD) to the upper third of the nasal passage of a subject such that it transits the blood brain barrier to treat various brain conditions.